(688302)"HINOVA PHARMACEUTICALS INC."Report for Q3 2026
Filed with SSE · Stock code 688302 · · 13 pages · Chinese
Hinova Pharmaceuticals, Inc. on 6ix
Earlier from Hinova Pharmaceuticals
- (688302)"HINOVA PHARMACEUTICALS INC."Announcement on Voluntary Disclosure of Phase IIa Clinical Trial Data of HP515 Tablets Being Accepted as a Late-Breaking Abstract at the Annual Meeting of the American Association for the Study of Liver Diseases
- Announcement on the Board Secretary's Receipt of the Qualification Training Certificate and Official Assumption of Duties
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
- Announcement on Public Solicitation of Voting Rights by CHINA SECURITIES INVESTOR SERVICES CENTER CO., LTD.
Later from Hinova Pharmaceuticals
All Hinova Pharmaceuticals news releasesFollow Hinova Pharmaceuticals into a list and get an email when it puts out news.
Follow Hinova Pharmaceuticals